Breast cancer
Artificial intelligence (AI) offers a promising approach to evaluating Ki67 in breast cancer. It allows for a more accurate, early, and precise assessment of this cellular proliferation marker, influencing treatment decisions and prognosis evaluation of the neoplasm. AI algorithms, trained with biopsy images and Ki67 data, can identify complex patterns with high precision that might escape the human eye. This synergy allows for quicker and more accurate quantification of Ki67, guiding the choice of the most effective therapy for each patient, as it is an independent prognostic factor for disease-free survival, overall survival, and response to chemotherapy.
DIGPATHO
What We Do
AI-powered Breast Cancer Diagnosis
We leverage artificial intelligence to enhance the accuracy and speed of breast cancer diagnosis, helping healthcare professionals make informed decisions.
Biomarker Analysis with AI
Our technology analyzes key biomarkers like KI67 and HER2 NEU to provide deeper insights into breast cancer classification and treatment planning.
Early Diagnosis, Better Results
By using AI-powered analytics, we aim to improve early diagnosis of breast cancer, increasing the chances of successful treatment and patient recovery.
We Revolutionize Breast Cancer Diagnosis with AI
Our advanced AI-powered solutions enhance breast cancer diagnosis by providing accurate, fast, and reliable biomarker analysis. By integrating cutting-edge technology into pathology workflows, we help healthcare professionals focus on what matters most—patient care.
Five Pillars. One Mission.
Our AI-driven technology is built on five key pillars: Accuracy, Speed, Innovation, Integration, and Patient-Centered Care. Together, they drive our mission to enhance breast cancer detection and improve patient outcomes.